[Administration of various dosages of retard isosorbide-5-mononitrate in patients with stable angina pectoris on combined therapy].
We studied efficiency of a retard form of isosorbide-5-mononitrate (Mono Mac 50D) in patients with stable angina pectoris (NYHA class II and III). This efficiency was assessed by clinical examinations and 24-h Holter ECG monitoring before and after the treatment. 16 patients with angina of functional class II and 12 patients with functional class III received combined treatment: prolonged mononitrate (Mono Mac 50D), disaggregants, beta-blockers, ACE inhibitors and calcium antagonists (on demand). In angina functional class II Mono Mac 50D was given in a single dose 50 mg/day (1 tablet) in the morning for 4 weeks, in functional class III angina the drug was taken for 2 weeks in a dose 50 mg/day, the next two weeks in a dose 100 mg/day once in the morning. The other drugs were taken in moderate recommended doses. After two weeks of treatment with 50 mg/day Mono Mac 50D angina symptoms attenuated (in functional class II) and the patients' condition improved (in functional class III). In elevation of the dose to 100 mg/day the latter patients improved still greater. We think it valid to use a single 50 mg/day dose in angina functional class II and 100 mg once a day in functional class III.
Chernova
E V
EV
Kuchinskaia
N G
NG
Barysheva
O V
OV
Bezborodova
Iu V
IuV
Shatukhina
E Iu
EIu
Aleshin
O I
OI
D000328:Adult; D000368:Aged; D000787:Angina Pectoris / Q000188:drug therapy*; D003692:Delayed-Action Preparations / Q000627:therapeutic use; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007548:Isosorbide Dinitrate / Q000031:analogs & derivatives / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D014665:Vasodilator Agents / Q000627:therapeutic use*
D003692:Delayed-Action Preparations; D014665:Vasodilator Agents; D007548:Isosorbide Dinitrate; C030397:isosorbide-5-mononitrate